234 related articles for article (PubMed ID: 34763611)
21. Generic anti-drug antibody assay with drug tolerance in serum samples from mice exposed to human antibodies.
Stubenrauch K; Mackeben K; Vogel R; Heinrich J
Anal Biochem; 2012 Nov; 430(2):193-9. PubMed ID: 22935295
[TBL] [Abstract][Full Text] [Related]
22. A systematic study of the effect of low pH acid treatment on anti-drug antibodies specific for a domain antibody therapeutic: Impact on drug tolerance, assay sensitivity and post-validation method assessment of ADA in clinical serum samples.
Kavita U; Duo J; Crawford SM; Liu R; Valcin J; Gleason C; Dong H; Gadkari S; Dodge RW; Pillutla RC; DeSilva BS
J Immunol Methods; 2017 Sep; 448():91-104. PubMed ID: 28625864
[TBL] [Abstract][Full Text] [Related]
23. Hydrogen exchange mass spectrometry reveals protein interfaces and distant dynamic coupling effects during the reversible self-association of an IgG1 monoclonal antibody.
Arora J; Hickey JM; Majumdar R; Esfandiary R; Bishop SM; Samra HS; Middaugh CR; Weis DD; Volkin DB
MAbs; 2015; 7(3):525-39. PubMed ID: 25875351
[TBL] [Abstract][Full Text] [Related]
24. Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor.
Datta-Mannan A; Witcher DR; Tang Y; Watkins J; Wroblewski VJ
J Biol Chem; 2007 Jan; 282(3):1709-17. PubMed ID: 17135257
[TBL] [Abstract][Full Text] [Related]
25. Sequestration of anti-platelet GPIIIa antibody in rheumatoid factor immune complexes of human immunodeficiency virus 1 thrombocytopenic patients.
Karpatkin S; Nardi MA; Hymes KB
Proc Natl Acad Sci U S A; 1995 Mar; 92(6):2263-7. PubMed ID: 7892259
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity screening assay development for a novel human-mouse chimeric anti-CD147 monoclonal antibody (Metuzumab).
Mi L; Li W; Li M; Chen T; Wang M; Sun L; Chen Z
J Immunol Methods; 2016 Jun; 433():38-43. PubMed ID: 26944771
[TBL] [Abstract][Full Text] [Related]
27. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
28. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
[TBL] [Abstract][Full Text] [Related]
29. An innovative method for characterizing neutralizing antibodies against antibody-derived therapeutics.
Coddens A; Snoeck V; Bontinck L; Buyse MA; Pine SO
J Immunol Methods; 2020 Dec; 487():112896. PubMed ID: 33065122
[TBL] [Abstract][Full Text] [Related]
30. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics.
Schoch A; Kettenberger H; Mundigl O; Winter G; Engert J; Heinrich J; Emrich T
Proc Natl Acad Sci U S A; 2015 May; 112(19):5997-6002. PubMed ID: 25918417
[TBL] [Abstract][Full Text] [Related]
31. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
[TBL] [Abstract][Full Text] [Related]
32. SEC Based Method for Size Determination of Immune Complexes of Therapeutic Antibodies in Animal Matrix.
Boysen M; Schlicksupp L; Dreher I; Loebbert R; Richter M
J Immunol Res; 2016; 2016():9096059. PubMed ID: 27556050
[TBL] [Abstract][Full Text] [Related]
33. Detection of low-affinity anti-drug antibodies and improved drug tolerance in immunogenicity testing by Octet(®) biolayer interferometry.
Li J; Schantz A; Schwegler M; Shankar G
J Pharm Biomed Anal; 2011 Jan; 54(2):286-94. PubMed ID: 20869832
[TBL] [Abstract][Full Text] [Related]
34. Characterization and screening of IgG binding to the neonatal Fc receptor.
Neuber T; Frese K; Jaehrling J; Jäger S; Daubert D; Felderer K; Linnemann M; Höhne A; Kaden S; Kölln J; Tiller T; Brocks B; Ostendorp R; Pabst S
MAbs; 2014; 6(4):928-42. PubMed ID: 24802048
[TBL] [Abstract][Full Text] [Related]
35. The Immunogenicity of Biologic Therapies.
Garcês S; Demengeot J
Curr Probl Dermatol; 2018; 53():37-48. PubMed ID: 29131036
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of automated Wes system as an analytical and characterization tool to support monoclonal antibody drug product development.
Wang J; Valdez A; Chen Y
J Pharm Biomed Anal; 2017 May; 139():263-268. PubMed ID: 28069351
[TBL] [Abstract][Full Text] [Related]
37. Charge-mediated Fab-Fc interactions in an IgG1 antibody induce reversible self-association, cluster formation, and elevated viscosity.
Arora J; Hu Y; Esfandiary R; Sathish HA; Bishop SM; Joshi SB; Middaugh CR; Volkin DB; Weis DD
MAbs; 2016; 8(8):1561-1574. PubMed ID: 27560842
[TBL] [Abstract][Full Text] [Related]
38. A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.
Souders CA; Nelson SC; Wang Y; Crowley AR; Klempner MS; Thomas W
MAbs; 2015; 7(5):912-21. PubMed ID: 26018774
[TBL] [Abstract][Full Text] [Related]
39. Human IgG rheumatoid factors and RF-like immune complexes induce IgG1 rheumatoid factor production in mice.
Abedi-Valugerdi M; Ridderstad A; al-Balaghi S; Möller E
Scand J Immunol; 1995 Jun; 41(6):575-82. PubMed ID: 7770728
[TBL] [Abstract][Full Text] [Related]
40. Identification and characterization of monoclonal antibody fragments cleaved at the complementarity determining region using orthogonal analytical methods.
Li W; Yang B; Zhou D; Xu J; Li W; Suen WC
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Mar; 1048():121-129. PubMed ID: 28242491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
